Skip to main content
SpringerLink
Log in

Differenzierte Taxan-Gabe bei frühem Brustkrebs

  • Literatur kompakt_Mammakarzinom und gynäkologische Tumoren
  • Published:
Im Focus Onkologie Aims and scope

In der adjuvanten Therapie des frühen nodal-positiven (N+) Mammakarzinoms sind Taxane mittlerweile Standard. Wie deutlich Patientinnen mit intermediärem Risiko davon profitieren, zeigt die EC-Doc-Studie der Westdeutschen Studiengruppe (WSG).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Nitz U et al. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: Efficacy and predictive value of Ki67 expression. Ann Oncol. 2014 May 14. [Epub ahead of print].

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Friederike Klein

Authors
  1. Friederike Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klein, F. Differenzierte Taxan-Gabe bei frühem Brustkrebs. Im Focus Onkologie 17, 32 (2014). https://doi.org/10.1007/s15015-014-1425-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-1425-2

Search

Navigation